Company: Cogentus Pharmaceuticals
Based: Menlo Park, CA
Investors: Pinnacle Ventures, Prospect Venture Partners, Undisclosed Investor
Scoop: Cogentus' lead therapy is CGT-2168, a once-daily oral formulation that combines clopidogrel with a gastroprotectant that is designed to significantly reduce the gastrointestinal side effects commonly associated with antiplatelet therapy. Two Phase III clinical trials of CGT-2168 are underway.